



PB 47 of 2025

National Health (Minimum Stockholding) Amendment Determination (No. 4) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 16 April 2025

Rebecca Richardson
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 May 2025	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
Schedule 2—Amendments commencing 1 October 2025	5
<i>National Health (Minimum Stockholding) Determination 2023</i>	5

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 4) 2025*.
- (2) This instrument may also be cited as PB 47 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 May 2025.	1 May 2025
2. Schedule 1	1 May 2025.	1 May 2025
3. Schedule 2	1 October 2025.	1 October 2025

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 May 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

Cefotaxime	Powder for injection 1 g (as sodium)	Injection	DBL Cefotaxime	between 1 April 2025 and 30 April 2025— 0 months stock by reference to usual demand
------------	---	-----------	----------------	---

2 Schedule 1 (table)

After:

Entecavir	Tablet 1 mg (as monohydrate)	Oral	Entecavir Viartis	after 28 February 2025— 4 months stock by reference to usual demand of both Entecavir Viartis and Entecavir Mylan added together
-----------	---------------------------------	------	-------------------	--

insert:

Erythromycin	Capsule 250 mg (containing enteric coated pellets)	Oral	Mayne Pharma Erythromycin	2 months stock by reference to usual demand
--------------	--	------	------------------------------	---

3 Schedule 1 (table)

After:

Methoxyflurane	Liquid for inhalation 999 mg per g, 3 ml (with inhaler)	Inhalation by mouth	Penthrox (Combination Pack)	6 months stock by reference to usual PBS demand
----------------	---	---------------------	--------------------------------	---

insert:

Methylprednisolone	Powder for injection 1 g (as sodium succinate)	Injection	Solu-Medrol	between 1 May 2025 and 31 May 2025— 0 months stock by reference to usual demand
--------------------	--	-----------	-------------	---

4 Schedule 1 (table)

Omit:

Methylprednisolone	Powder for injection 40 mg (as sodium succinate) with diluent	Injection	Solu-Medrol	between 1 April 2025 and 30 April 2025— 0 months stock by reference to usual demand
--------------------	--	-----------	-------------	---

5 Schedule 1 (table)

After:

Montelukast	Tablet, chewable, 5 mg (as sodium)	Oral	APX-Montelukast	4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together
-------------	------------------------------------	------	-----------------	---

insert:

Montelukast	Tablet, chewable, 5 mg (as sodium)	Oral	Montelukast Viatris	after 31 August 2025—4 months stock by reference to usual demand of both Montelukast Viatris and Montelukast Mylan added together
-------------	------------------------------------	------	---------------------	---

6 Schedule 1 (table)

Omit:

Perindopril	Tablet containing perindopril erbumine 2 mg	Oral	Indosyl Mono 2	between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand
Perindopril	Tablet containing perindopril erbumine 4 mg	Oral	Indosyl Mono 4	between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand
Perindopril	Tablet containing perindopril erbumine 8 mg	Oral	Indosyl Mono 8	between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand
Perindopril with indapamide	Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	Oral	Indosyl Combi 4/1.25	between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand

7 Schedule 1 (table)

Omit:

Polyethylene glycol 400 with propylene glycol	Eye drops 4 mg-3 mg per mL, 15 mL	Application to the Eye	Optix	between 1 February 2025 and 30 April 2025—0 months stock by reference to usual demand
---	-----------------------------------	------------------------	-------	---

8 Schedule 1 (table)

After:				
Sumatriptan	Tablet 50 mg (as succinate)	Oral	APO-Sumatriptan	4 months stock by reference to usual demand
insert:				
Sumatriptan	Tablet 50 mg (as succinate)	Oral	Imigran	between 1 April 2025 and 30 June 2025— 0 months stock by reference to usual demand
Sumatriptan	Tablet 50 mg (as succinate)	Oral	Imigran Migraine	between 1 April 2025 and 30 June 2025— 0 months stock by reference to usual demand

Schedule 2—Amendments commencing 1 October 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:				
Chlortalidone	Tablet 25 mg	Oral	Hygroton 25	4 months stock by reference to usual PBS demand
insert:				
Choriogonadotropin alfa	Solution for injection 250 micrograms in 0.5 mL pre-filled pen	Injection	Ovidrel	6 months stock by reference to usual PBS demand

2 Schedule 1 (table)

After:				
Levetiracetam	Tablet 250 mg	Oral	Levetiracetam Viatris	after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together
insert:				
Levonorgestrel	Intrauterine drug delivery system 52 mg	Intrauterine	Mirena	6 months stock by reference to usual PBS demand

3 Schedule 1 (table)

After:				
Triglycerides - medium chain, formula	Oral powder 400 g (Lipistart)	Oral	Lipistart	0 months stock by reference to usual PBS demand
insert:				
Triglycerides, long chain with glucose polymer	Oral liquid 1 L, 6 (ProZero)	Oral	ProZero	6 months stock by reference to usual PBS demand